Mounjaro®
Starting from £179.99/mo
Start journey Learn more"Mounjaro face" is a colloquial term for the visible facial changes some people notice during tirzepatide treatment, particularly as body fat redistributes during significant weight loss. It typically refers to a leaner, sometimes hollower appearance around the cheeks, jaw and temples. These changes are not a side effect of the medicine itself but a natural consequence of losing a meaningful amount of weight — and they raise real questions worth thinking through carefully before you start. The decision most people face is not whether to treat their weight, but how to feel informed and prepared for what that journey changes, including in the mirror.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people ask "what is Mounjaro face", they are usually describing a noticeable slimming around the mid-face, cheeks and jaw that appears as weight comes off during tirzepatide treatment. The medicine works by activating GIP and GLP-1 receptors, reducing appetite and slowing the rate at which the stomach empties, which leads many people to eat considerably less over time. That sustained calorie deficit produces body-wide fat reduction, and the face is not exempt.
Fat sits in distinct compartments under the facial skin, and those compartments thin as overall fat mass falls. The cheeks, temples and the area under the eyes are particularly noticeable because we look at faces closely. There is nothing unique happening to tirzepatide users here: the same changes occur with any substantial weight loss, whether through surgery, diet or another medicine. What differs with GLP-1 treatments is the speed and scale of loss; in the SURMOUNT-1 clinical trial, participants lost around 20–21% of their body weight over 72 weeks at the highest dose, and you can read the full published findings via the SURMOUNT-1 paper in the New England Journal of Medicine.
Speed matters here. Slower loss gives skin more time to adapt. Rapid changes can leave skin looking less supported, which is why the "hollowed" look is more pronounced in some people than others. Age amplifies this: facial fat in middle age acts partly as scaffolding, and once it reduces, skin with less elasticity takes longer to readjust. That is the honest picture.
People often wonder whether "Mounjaro face" will happen to them. The honest answer is that some degree of facial change is likely if you lose a significant amount of weight. Whether that change bothers you depends on several things: your starting point, how much weight you lose in total, your age, skin quality and (perhaps most importantly) whether you were hoping to see the change or fearing it.
Younger patients and those with good baseline skin elasticity often find the face settles into a more defined shape within a few months. Older patients, or those losing weight quickly from a high starting point, are more likely to notice a drawn or deflated quality that takes longer to resolve, or may not resolve fully without other interventions. That is not a reason to avoid treatment if weight is affecting your health; it is information worth having before you start.
The practical decision most people are weighing is this: the health benefits of meaningful weight loss are well-documented and substantial, and the risk of facial hollowing is a cosmetic concern to consider alongside them, not instead. Our clinical team routinely talks patients through what to expect from their face and skin during treatment, it is one of the most common conversations prescribers have.
If you are also concerned about whether facial changes differ with the active ingredient versus the brand name, the discussion on our tirzepatide and facial changes page covers that clearly.
There is no way to direct where your body loses fat, that is genetically determined. What you can influence is the condition of your skin and the support structure underneath it.
Protein is the first lever. When appetite falls sharply on tirzepatide, many people inadvertently under-eat protein, which accelerates muscle loss and leaves skin looking thin and poorly supported. Aiming for adequate protein at each meal (lean meat, fish, eggs, legumes, Greek yoghurt) helps preserve the lean mass that gives the face structure. Hydration matters for the same reason: skin that is well-hydrated maintains more resilience.
Strength and resistance exercise is the second lever. Building or maintaining muscle mass during weight loss keeps the face and neck area looking more supported. It also slows the speed at which subcutaneous fat depletes. Our practical guidance for Mounjaro users covers the lifestyle habits that people find most useful during treatment, including nutrition timing and activity suggestions.
Sun protection and a consistent skincare routine also help: collagen degradation accelerates with UV exposure, so maintaining a simple regime during treatment supports skin quality. None of these measures guarantee a particular outcome, but they genuinely shift the probabilities in your favour.
If you are curious about what the broader range of facial skin changes during treatment looks like, including how a Mounjaro face rash can present alongside other skin reactions, our page on Mounjaro, facial ageing and skin changes goes deeper on the skin science.
Not everyone is troubled by what happens to their face. Many people who carry significant excess weight find the gradual emergence of sharper features welcome, and report feeling more like themselves in the mirror. That experience is just as valid as the person who is surprised and unsettled by a hollower look.
If you find the facial changes genuinely distressing, it is worth mentioning this to your prescriber. It will not necessarily change your treatment, but it might affect the pace of dose progression, nutritional advice or the decision to refer you for a skin or aesthetic consultation. It is also worth knowing that some degree of facial readjustment continues for months after weight stabilises, the face is not static.
One practical note: if you are planning to start treatment around a significant event (a wedding, a holiday, a set of family photos) timing matters. Our page on how Mounjaro weight loss affects the face gives a fuller picture of what to expect and when, which is worth reading before you decide when to begin. If you are thinking about the cost side of treatment more broadly, our Mounjaro UK pricing page covers how the cost landscape has shifted and what to expect.
These are prescription-only medicines and a prescriber reviews every consultation individually before anything is approved, drawing on your full health picture. The NHS tirzepatide page gives a clear overview of the medicine's licensed use and common side effects if you want an independent starting point. When you are ready to talk through whether treatment is right for you, speaking to our prescribers is the right next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.